Table 3

Risk of lung cancer related to CYP2A13 genotypes by smoking status and pack-years smoked

Smoking statusCC genotypeCT + TT genotypeOR (95% CI)aP
Cases/controlsCases/controls
Adenocarcinoma
 Nonsmokers165/38121/760.60 (0.35–1.01)0.086
 Smokers123/27110/630.34 (0.17–0.69)0.003
  <27 pack-years56/1474/410.23 (0.08–0.68)0.008
  ≥27 pack-years67/1246/220.47 (0.18–1.25)0.130
Squamous cell carcinoma
 Nonsmokers44/38111/761.31 (0.64–2.68)0.456
 Smokers175/27133/630.83 (0.52–1.33)0.445
  <27 pack-years56/14710/410.65 (0.30–1.40)0.272
  ≥27 pack-years119/12423/221.13 (0.59–2.16)0.704
Otherb
 Nonsmokers55/3817/760.59 (0.25–1.34)0.206
 Smokers70/27110/630.62 (0.30–1.28)0.198
  <27 pack-years29/1471/410.09 (0.01–0.72)0.023
  ≥27 pack-years41/1249/221.25 (0.53–2.97)0.612
All cases
 Nonsmokers264/38139/760.71 (0.47–1.09)0.110
 Smokers368/27153/630.62 (0.42–0.93)0.020
  <27 pack-years141/14715/410.37 (0.19–0.69)0.002
  ≥27 pack-years227/12438/220.95 (0.53–1.69)0.857
  • a ORs and 95% CIs were calculated by logistic regression with the CC genotype as reference group and adjusted for age, sex, and pack-years within the strata.

  • b Other includes undifferentiated cancer (n = 60), bronchioalveolar carcinoma (n = 27), and small cell carcinoma (n = 55).